Isis Pharmaceuticals' CEO Discusses KYNAMRO's EMDAC Meeting Update (Transcript)

Isis Pharmaceuticals, Inc. (ISIS) Special Call October 18, 2012 7:30 PM ET

Executives

Stanley Crooke - Chairman of the Board, President, Chief Executive Officer
Wade Walke - Executive Director Corp. Communications & Investor Relations
Lynne Parshall - Chief Operating Officer and Chief Financial Officer
Richard Geary - Senior Vice President of Development

Analysts

Jim Birchenough - BMO Capital
Stephen Willey - Stifel Nicolaus
Chad Messer - Needham & Company
Edward Tenthoff - Piper Jaffray
Charles Polsky - William Harris Investors

Operator

Good day, ladies and gentlemen and welcome to the Isis Pharmaceuticals' conference call to review the FDA advisory committee panel vote of KYNAMMRO. As a reminder, this call is being recorded for replay purposes.

I would now like to hand the call over to your host for today, Dr. Stanley Crooke, Chairman and CEO. Proceed, sir.

Stanley Crooke

Thank you. Good evening and thanks everyone for joining us on the call today. I will review the recommendations made by the FDA advisory committee panel and then we will open up the call for Q&A.

Joining me on the call are our Lynne Parshall, our Chief Operating Officer and CFO, Richard Geary, Senior Vice President of Development, Walter Singleton, Vice President, Development and Chief Medical Officer and Wade Walke, Executive Director of Corporate Communications & Investor Relations.

Wayde, would you please read our forward-looking language statement?

Wade Walke

Yes. Thanks, Stan. A reminder to everyone that this webcast includes forward-looking statement regarding the development activity in therapeutic and commercial potential on the safety of KYNAMRO. These statement describing Isis's goals, expectations, financial or other projections, intentions or beliefs including the planned commercialization of KYNAMRO in the forward-looking statement and should be considered an at-risk statement.

Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of